Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI NASDAQ:EXOZ NASDAQ:GDTC NASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$1.19-1.7%$0.89$0.65▼$1.60$44.09M1.15279,369 shs105,104 shsEXOZeXoZymes$4.71+0.2%$7.91$4.66▼$18.40$43.29M2.7314,991 shs5,832 shsGDTCCytoMed Therapeutics$0.99+12.5%$1.07$0.68▼$3.68$10.41M0.0110,080 shs3.12 million shsINMBINmune Bio$1.62-5.8%$1.55$1.09▼$3.24$45.73M0.97959,410 shs186,095 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International-1.65%-5.56%+62.79%+38.37%+8.18%EXOZeXoZymes+0.73%-17.18%-34.85%-54.32%-50.42%GDTCCytoMed Therapeutics+12.50%-1.00%-3.88%+4.13%-47.62%INMBINmune Bio-5.81%-14.74%+20.00%+16.55%-43.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$1.19-1.7%$0.89$0.65▼$1.60$44.09M1.15279,369 shs105,104 shsEXOZeXoZymes$4.71+0.2%$7.91$4.66▼$18.40$43.29M2.7314,991 shs5,832 shsGDTCCytoMed Therapeutics$0.99+12.5%$1.07$0.68▼$3.68$10.41M0.0110,080 shs3.12 million shsINMBINmune Bio$1.62-5.8%$1.55$1.09▼$3.24$45.73M0.97959,410 shs186,095 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International-1.65%-5.56%+62.79%+38.37%+8.18%EXOZeXoZymes+0.73%-17.18%-34.85%-54.32%-50.42%GDTCCytoMed Therapeutics+12.50%-1.00%-3.88%+4.13%-47.62%INMBINmune Bio-5.81%-14.74%+20.00%+16.55%-43.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 2.33Hold$3.00152.10% UpsideEXOZeXoZymes 1.00SellN/AN/AGDTCCytoMed Therapeutics 1.00SellN/AN/AINMBINmune Bio 2.50Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest GDTC, EXOZ, DYAI, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026INMBINmune Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/8/2026GDTCCytoMed Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/11/2026INMBINmune Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/29/2026EXOZeXoZymes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.09M14.03N/AN/A$0.03 per share39.67EXOZeXoZymesN/AN/AN/AN/A$0.40 per shareN/AGDTCCytoMed Therapeutics$250K46.85N/AN/A$0.45 per share2.20INMBINmune BioN/AN/AN/AN/A$0.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$7.36M-$0.23N/AN/AN/A-192.40%-1,005.45%-77.64%8/12/2026 (Estimated)EXOZeXoZymes-$9.16M-$1.14N/AN/AN/AN/A-220.63%-141.26%N/AGDTCCytoMed Therapeutics-$3.10MN/AN/AN/AN/AN/AN/AN/AN/AINMBINmune Bio-$45.93M-$1.67N/AN/AN/AN/A-103.03%-77.66%8/6/2026 (Estimated)Latest GDTC, EXOZ, DYAI, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026DYAIDyadic International-$0.03N/AN/AN/A$1.03 millionN/A8/6/2026Q2 2026INMBINmune Bio-$0.2067N/AN/AN/A$1.16 millionN/A5/14/2026Q1 2026EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A5/13/2026Q1 2026DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$0.90 million$1.11 million5/7/2026Q1 2026INMBINmune Bio-$0.2450-$0.20+$0.0450-$0.20$1.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International4.082.422.42EXOZeXoZymes0.031.321.32GDTCCytoMed Therapeutics0.065.175.17INMBINmune BioN/A4.244.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%EXOZeXoZymesN/AGDTCCytoMed Therapeutics0.04%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipDYAIDyadic International20.90%EXOZeXoZymes72.41%GDTCCytoMed TherapeuticsN/AINMBINmune Bio21.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International736.44 million28.82 millionOptionableEXOZeXoZymes299.21 million2.54 millionN/AGDTCCytoMed TherapeuticsN/A11.83 millionN/ANot OptionableINMBINmune Bio1026.59 million20.90 millionOptionableGDTC, EXOZ, DYAI, and INMB HeadlinesRecent News About These CompaniesWall Street Zen Downgrades INmune Bio (NASDAQ:INMB) to SellJuly 25 at 1:24 AM | americanbankingnews.comINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ PlatformJuly 20, 2026 | globenewswire.comINmune Bio Study Finds Soluble TNF Inhibition with XPro1595 Prevents TBI-Driven Amyloid Pathology in Alzheimer’s ModelJuly 15, 2026 | quiverquant.comQINmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical StudyJuly 15, 2026 | globenewswire.comWall Street Zen Upgrades INmune Bio (NASDAQ:INMB) to "Hold"July 12, 2026 | marketbeat.comINmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAICJuly 9, 2026 | markets.businessinsider.comINmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAICJuly 9, 2026 | globenewswire.comINmune Bio Inc. Common stock (INMB) Insider ActivityJuly 2, 2026 | nasdaq.comINmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written OpinionJuly 1, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)June 25, 2026 | theglobeandmail.comINmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™June 25, 2026 | globenewswire.comINmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEBJune 23, 2026 | globenewswire.comINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's TrialJune 2, 2026 | globenewswire.comINMB Share News TodayMay 19, 2026 | uk.investing.comINmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ PlatformMay 15, 2026 | globenewswire.comINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseMay 14, 2026 | globenewswire.comINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection PointMay 13, 2026 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call TranscriptMay 10, 2026 | insidermonkey.comINmune Bio (INMB) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comINmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 8, 2026 | seekingalpha.comINmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform ...May 7, 2026 | caledonianrecord.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGDTC, EXOZ, DYAI, and INMB Company DescriptionsDyadic International NASDAQ:DYAI$1.19 -0.02 (-1.65%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.18 -0.01 (-1.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.eXoZymes NASDAQ:EXOZ$4.71 +0.01 (+0.21%) Closing price 07/24/2026 03:57 PM EasternExtended Trading$4.64 -0.07 (-1.49%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.CytoMed Therapeutics NASDAQ:GDTC$0.99 +0.11 (+12.50%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$1.00 +0.01 (+0.61%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.INmune Bio NASDAQ:INMB$1.62 -0.10 (-5.81%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.66 +0.04 (+2.78%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
